Pfizer’s 2025 forecast meets expectations and leaves room for debate

Taking stock of the drug industry, from the lab to the medicine chest

December 17, 2024 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Michael M. Santiago/Getty Images STAT+ | Pfizer's 2025 forecast meets expectations and leaves room for debate The company expects sales and earnings to meet analysts' forecasts, but it still faces questions about its pipeline. By Matthew Herper STAT+ | Truth-teller or reflexive contrarian: Which Marty Makary would run the FDA? Makary is a long-time critic of the medical establishment who's now set to regulate food, drugs, and medical devices at the FDA. By Lizzy Lawrence STAT+ | Sanofi is the latest drug company to sue HHS over payment terms for 340B hospitals This is the fourth time that a pharmaceutical company has gone to court in recent weeks over such a dispute over the 340B discount program. By Ed Silverman Adobe STAT+ | Opinion: Pharmacy benefits managers should be worried As a former FTC policy director, I think the new Trump administration is going to finish off the PBM reform begun during his first presidency. By David Balto

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser